Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies

Lung Cancer

Volumn 76, Issue 2, 2012, Pages 177-182

  Tan, Fenlai ^a   Shen, Xiaoyan ^a   Wang, Dechang ^b   Xie, Guojian ^c   Zhang, Xiaodong ^c   Ding, Lieming ^a   Hu, Yunyan ^a   He, Wei ^a   Wang, Yanping ^a   Wang, Yinxiang ^a  

^a Zhejiang Beta Pharma Inc   (China)

^b CANCER HOSPITAL   (China)

^c Beta Pharma Inc   (United States)

Author keywords

EGFR mutation; EGFR TKIs; Icotinib; In vivo; NSCLC

Indexed keywords

BPI 2009H; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; ICOTINIB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN PHOSPHORYLATION; SQUAMOUS CELL CARCINOMA; TUMOR CELL; WEIGHT REDUCTION; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CROWN ETHERS; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TYROSINE;

EID: 84859435053     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.10.023     Document Type: Article

References (27)

1. Salomon D.S., Brandt R., Ciardiello F., Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995, 19:183-232.
2. Liu D., Jiang J., Hu P., Tan F., Wang Y. Quantitative determination of icotinib in human plasma and urine using liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B 2009, 877(30):3781-3786.
3. Zhao Q., Zhang L., Jiang J., Xu L., Shentu J., Liu D., et al. Icotinib, a potent and selective oral EGFR inhibitor, is well tolerated and active in patients with NSCLC: results from a phase I/II trial. 13th world conference on lung cancer (WCLC) 2009.
4. Zhao Q., Shentu J., Xu N., Zhou J., Yang G., Yao Y., et al. Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors. Lung Cancer 2011, 73(August (2)):195-202.
5. Zhao Q., Zhou J., Shentu J., Xu N., Tan F. A phase I/IIa study of icotinib hydrochloride, a novel oral EGFR-TKI, to evaluate its safety, tolerance, and preliminary efficacy in advanced NSCLC patients in China. ASCO 2010 meeting report 2010.
6. ClinicalTrials.gov. Safety and efficacy study of Icotinb in non-small cell lung cancer (NSCLC) patients (ICOGEN). ClinicalTrials.gov identifier . Available at: [accessed January 16, 2011]. http://clinicaltrials.gov/.
7. Sun Y., Shi Y., Zhang L., Liu X., Zhou C., Zhang L., et al. A randomized, double-blind phase III study of icotinib versus gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (ICOGEN). J Clin Oncol 2011, 29(Suppl.). [abstr 7522].
8. Sun Y., Shi Y., Zhang L., Liu X., Zhou C., Wang D., et al. A randomized, double-blind phase III study of Icotinib versus Gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy(ICOGEN). 14th world conference on lung cancer (WCLC 2011, [abstr O10.06].
9. Liu D., Jiang J., Zhang L., Tan F., Wang Y., Hu P. Metabolite characterization of a novel anti-cancer agent, icotinib, in humans through liquid chromatography/quadrupole time-of-flight tandem mass spectrometry. Rapid Commun Mass Spectrom 2011, 25(15):2131-2140.
10. Ren G., Zhao Y., Zhu Y. Tumor gene mutations and messenger RNA expression: correlation with clinical response to icotinib hydrochloride in non-small cell lung cancer. Chin Med J 2011, 124(1):19-25.
11. Fantl W.J., Johnson D.E., Williams L.T. Signaling by receptor tyrosine kinases. Annu Rev Biochem 1993, 62:453-481.
12. Jorissen R.N., Walker F., Pouliot N., Garrett T.P., Ward C.W., Burgess A.W. Epidermal growth factor receptor: mechanisms of activation and signaling. Exp Cell Res 2003, 284:31-53.
13. Kari C., Chan T.O., Quadros M.R., Rodeck U. Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage. Cancer Res 2003, 63:1-5.
14. Nicholson R.I., Gee J.M., Harper M.E. EGFR and cancer prognosis. Eur J Cancer 2001, 37:9-15.
15. Fry D.W., Kraker A.J., McMichael A., Ambroso L.A., Nelson J.M., Leopold W.R., et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 1994, 265:1093-1095.
16. Traxler P., Bold G., Frei J., Lang M., Lydon N., Mett H., et al. Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines. J Med Chem 1997, 40:3601-3616.
17. Traxler P., Bold G., Buchdunger E., Caravatti G., Furet P., Manley P., et al. Tyrosine kinase inhibitors: from rational design to clinical trials. Med Res Rev 2001, 21:499-512.
18. Harandi A., Zaidi A.S., Stocker A.M., Laber D.A., Clinical Efficacy Toxicity of anti-EGFR therapy in common cancers. J Oncol 2009, 2009:567486.
19. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Qizumi S., Isobe H., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
20. Fukuoka M., Yano S., Giaccone G., Takagawa K., Douillard J.Y., Nishiwaki Y., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial). J Clin Oncol 2003, 21:2237-2246.
21. Perez-Soler R., Chachoua A., Hammond L.A., Rowinsky E.K., Huberman M., Karp D., et al. Determinants of tumor response and survival with erlotinib in patients with non-small cell lung cancer. J Clin Oncol 2004, 22:3238-3247.
22. Kris M.G., Natale R.B., Herbst R.S., Lynch T.J., Prager D., Belani C.P., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with nonsmall cell lung cancer: a randomized trial. JAMA 2003, 290:2149-2158.
23. Kim E.S., Hirsh V., Mok T., Socinski M.A., Gervais R., Wu Y.L., et al. Gefetinib versus docetaxel in previously treated non-small-cell lung caner (INTEREST): a randomised phase III trial. Lancet 2008, 372:1809-1818.
24. Ohe Y., Ichinose Y., Nishiwaki Y., Yamamoto N., Negoro S., Duffield E., et al. Phase III, randomized, open-label, first-line study of gefitinib(G) versus caboplatin/paclitaxel (C/P) in selected patients(pts) with advanced non-small-cell lung cancer(NSCLC) (IPASS): evaluation of recruits in Japan. J Clin Oncol 2009, 27(Suppl.):8044.
25. Qin B., Chen X., Zhu J., Pei D. Identification of EGFR kinase domain mutations among lung cancer patients in China: implication for targeted cancer therapy. Cell Res 2005, 15:212-217.
26. Tang P.A., Tsao M.S., Moore M.J. A review of erlotinib and its clinical use. Expert Opin Pharmacother 2006, 7:177-193.
27. Madhusudan S., Ganesan T.S. Tyrosine kinase inhibitors in cancer therapy. Clin Biochem 2004, 37:618-635.